Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update.

6073Background: Selpercatinib, is a first-in-class, highly selective, CNS active and potent RET inhibitor approved in multiple countries for treatment of RET-fusion positive lung or thyroid cancers...